{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:52:44Z","timestamp":1790855564778,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021QH035"],"award-info":[{"award-number":["ZR2021QH035"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021LSW011"],"award-info":[{"award-number":["ZR2021LSW011"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204221"],"award-info":[{"award-number":["82204221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073888"],"award-info":[{"award-number":["82073888"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016109","name":"Taishan Industry Leading Talents","doi-asserted-by":"publisher","award":["tscx202312146"],"award-info":[{"award-number":["tscx202312146"]}],"id":[{"id":"10.13039\/501100016109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202211112"],"award-info":[{"award-number":["tsqn202211112"]}],"id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202211112"],"award-info":[{"award-number":["tsqn202211112"]}],"id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Project of Yantai","award":["2023XDRH008"],"award-info":[{"award-number":["2023XDRH008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11030-024-11043-z","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T21:52:42Z","timestamp":1732312362000},"page":"4419-4431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Design, synthesis, and biological evaluation of novel molecules as potent inhibitors of indoleamine 2,3-dioxygenase 1"],"prefix":"10.1007","volume":"29","author":[{"given":"Shujuan","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"key":"11043_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","volume":"11","author":"JA Marin-Acevedo","year":"2018","unstructured":"Marin-Acevedo JA, Dholaria B, Soyano AE et al (2018) Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol 11:39. https:\/\/doi.org\/10.1186\/s13045-018-0582-8","journal-title":"J Hematol Oncol"},{"key":"11043_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00281-018-0702-0","volume":"41","author":"AJ Muller","year":"2019","unstructured":"Muller AJ, Manfredi MG, Zakharia Y et al (2019) Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Semin Immunopathol 41:41\u201348. https:\/\/doi.org\/10.1007\/s00281-018-0702-0","journal-title":"Semin Immunopathol"},{"key":"11043_CR3","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-18-2882","volume":"25","author":"BW Labadie","year":"2019","unstructured":"Labadie BW, Bao R, Luke JJ (2019) Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis. Clin Cancer Res 25:1462\u20131471. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2882","journal-title":"Clin Cancer Res"},{"key":"11043_CR4","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1021\/acsmedchemlett.6b00391","volume":"8","author":"EW Yue","year":"2017","unstructured":"Yue EW, Sparks R, Polam P et al (2017) INCB24360 (Epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immuno-oncology. ACS Med Chem Lett 8:486\u2013491. https:\/\/doi.org\/10.1021\/acsmedchemlett.6b00391","journal-title":"ACS Med Chem Lett"},{"key":"11043_CR5","doi-asserted-by":"publisher","first-page":"295101","DOI":"10.1088\/1361-6528\/ab824d","volume":"31","author":"Z Hu","year":"2020","unstructured":"Hu Z, Zheng B, Xu J et al (2020) An albumin-bound drug conjugate of paclitaxel and indoleamine-2,3-dioxygenase inhibitor for enhanced cancer chemo-immunotherapy. Nanotechnology 31:295101. https:\/\/doi.org\/10.1088\/1361-6528\/ab824d","journal-title":"Nanotechnology"},{"key":"11043_CR6","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1158\/1535-7163.MCT-17-1104","volume":"17","author":"B Gomes","year":"2018","unstructured":"Gomes B, Driessens G, Bartlett D et al (2018) Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271\/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy. Mol Cancer Ther 17:2530\u20132542. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-1104","journal-title":"Mol Cancer Ther"},{"key":"11043_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.canlet.2019.05.003","volume":"457","author":"R Saleh","year":"2019","unstructured":"Saleh R, Elkord E (2019) Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Lett 457:168\u2013179. https:\/\/doi.org\/10.1016\/j.canlet.2019.05.003","journal-title":"Cancer Lett"},{"key":"11043_CR8","doi-asserted-by":"publisher","first-page":"6985","DOI":"10.1158\/1078-0432.CCR-11-1331","volume":"17","author":"J Godin-Ethier","year":"2011","unstructured":"Godin-Ethier J, Hanafi LA, Piccirillo CA et al (2011) Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 17:6985\u20136991. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1331","journal-title":"Clin Cancer Res"},{"key":"11043_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4155\/fmc.14.151","volume":"7","author":"T Jiang","year":"2015","unstructured":"Jiang T, Sun Y, Yin Z et al (2015) Research progress of indoleamine 2,3-dioxygenase inhibitors. Future Med Chem 7:185\u2013201. https:\/\/doi.org\/10.4155\/fmc.14.151","journal-title":"Future Med Chem"},{"key":"11043_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00262-014-1549-4","volume":"63","author":"GC Prendergast","year":"2014","unstructured":"Prendergast GC, Smith C, Thomas S et al (2014) Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother 63:721\u2013735. https:\/\/doi.org\/10.1007\/s00262-014-1549-4","journal-title":"Cancer Immunol Immunother"},{"key":"11043_CR11","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1080\/07391102.2019.1615000","volume":"38","author":"S Jain","year":"2020","unstructured":"Jain S, Bhardwaj B, Amin SA et al (2020) Exploration of good and bad structural fingerprints for inhibition of indoleamine-2,3-dioxygenase enzyme in cancer immunotherapy using Monte Carlo optimization and Bayesian classification QSAR modeling. J Biomol Struct Dyn 38:1683\u20131696. https:\/\/doi.org\/10.1080\/07391102.2019.1615000","journal-title":"J Biomol Struct Dyn"},{"key":"11043_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1158\/1535-7163.MCT-20-0251","volume":"20","author":"A Balog","year":"2021","unstructured":"Balog A, Lin TA, Maley D et al (2021) Preclinical characterization of linrodostat mesylate, a novel, potent, and selective oral indoleamine 2,3-dioxygenase 1 inhibitor. Mol Cancer Ther 20:467\u2013476. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0251","journal-title":"Mol Cancer Ther"},{"key":"11043_CR13","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.1021\/acs.jmedchem.9b00662","volume":"62","author":"S Kumar","year":"2019","unstructured":"Kumar S, Waldo JP, Jaipuri FA et al (2019) Discovery of clinical candidate (1R,4r)-4-((R)-2-((S)-6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (navoximod), a potent and selective inhibitor of indoleamine 2,3-dioxygenase 1. J Med Chem 62:6705\u20136733. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00662","journal-title":"J Med Chem"},{"key":"11043_CR14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long GV, Dummer R, Hamid O et al (2019) Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol 20:1083\u20131097. https:\/\/doi.org\/10.1016\/S1470-2045(19)30274-8","journal-title":"Lancet Oncol"},{"key":"11043_CR15","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1124\/dmd.116.070680","volume":"44","author":"J Boer","year":"2016","unstructured":"Boer J, Young-Sciame R, Lee F et al (2016) Roles of UGT, P450, and gut microbiota in the metabolism of epacadostat in humans. Drug Metab Dispos 44:1668\u20131674. https:\/\/doi.org\/10.1124\/dmd.116.070680","journal-title":"Drug Metab Dispos"},{"key":"11043_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-024-10837-5","author":"G Lanka","year":"2024","unstructured":"Lanka G, Banerjee S, Adhikari N et al (2024) Fragment-based discovery of new potential DNMT1 inhibitors integrating multiple pharmacophore modeling, 3D-QSAR, virtual screening, molecular docking, ADME, and molecular dynamics simulation approaches. Mol Divers. https:\/\/doi.org\/10.1007\/s11030-024-10837-5","journal-title":"Mol Divers"},{"key":"11043_CR17","doi-asserted-by":"publisher","first-page":"113986","DOI":"10.1016\/j.ejmech.2021.113986","volume":"228","author":"Y Yang","year":"2022","unstructured":"Yang Y, Wang Y, Zuo A et al (2022) Synthesis, biological, and structural explorations of a series of mu-opioid receptor (MOR) agonists with high G protein signaling bias. Eur J Med Chem 228:113986. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113986","journal-title":"Eur J Med Chem"},{"key":"11043_CR18","doi-asserted-by":"publisher","first-page":"107481","DOI":"10.1016\/j.compbiomed.2023.107481","volume":"166","author":"G Lanka","year":"2023","unstructured":"Lanka G, Begum D, Banerjee S et al (2023) Pharmacophore-based virtual screening, 3D QSAR, docking, ADMET, and MD simulation studies: an in silico perspective for the identification of new potential HDAC3 inhibitors. Comput Biol Med 166:107481. https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107481","journal-title":"Comput Biol Med"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11043-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-11043-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11043-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T04:04:02Z","timestamp":1758600242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-11043-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["11043"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-11043-z","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,23]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}